Verastem Inc(NASDAQ:VSTM) announced the earnings results for Fiscal Year 2016 and Q4. The results came in during After-Market on Mar 23, 2017. Based on the corporate Earnings and Guidance, many Investment Banking firms balance their portfolio to Sell and Buy Stocks based on their strategy of investing in stocks.Earnings per share were $-0.32. The reported EPS was below estimates by -23.08%. Analysts had estimated an EPS of $-0.26.
Verastem Inc (VSTM) made into the market gainers list on Fridays trading session with the shares advancing 9.93% or 0.15 points. Due to strong positive momentum, the stock ended at $1.66, which is also near the day’s high of $1.78. The stock began the session at $1.7 and the volume stood at 11,69,747 shares. The 52-week high of the shares is $1.93 and the 52 week low is $1.05. The company has a current market capitalization of $61 M and it has 3,69,92,418 shares in outstanding.
Several Insider Transactions has been reported to the SEC. On Jun 30, 2015, Monica Singh (General Counsel) purchased 1,000 shares at $6.95 per share price.Also, On Jun 30, 2015, John B Green (CFO) purchased 500 shares at $7.12 per share price.On Jun 30, 2015, Robert Forrester (CEO) purchased 2,000 shares at $7.11 per share price, according to the Form-4 filing with the securities and exchange commission.
Verastem Inc. is a biopharmaceutical company. The Company is focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells. The Company’s programs target the Focal Adhesion Kinase (FAK) and the PI3K/mTOR signaling pathways. The Company has technology to create a stable population of cancer stem cells that it uses to screen for and identify small molecule compounds that target cancer stem cells. The Company’s solution includes the discovery and development of oncology therapeutics targeting cancer stem cells (CSCs). The Company is engaged in running clinical trials in cancers where CSCs were implicated in disease progression including mesothelioma ovarian non-small cell lung and other cancers such as breast cancer. The Company’s candidates include its FAK inhibitors VS-6063 and VS-4718 and VS-5584 its dual mTORC1/2 and PI3K inhibitor.